CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

Home About What We Do Programs and Services CADTH Reimbursement Review Adalimumab

Adalimumab

Last Updated: July 12, 2007

Result type: Reports

Project Number: SR0105-000

Product Line: Reimbursement Review

Generic Name: Adalimumab

Brand Name: Humira

Manufacturer: Abbott Laboratories, Limited

Therapeutic Area: Crohn's disease

Indications: Crohn's disease

Submission Type: Resubmission

Project Status: Complete

Date Recommendation Issued: December 19, 2007

Recommendation Type: List with clinical criteria and/or conditions

Adalimumab

Files